LifeStance Health Group, Inc. (LFST) saw its stock soar 10.00% in pre-market trading following the release of its second-quarter 2025 financial results, which surpassed analysts' expectations across key metrics.

The company reported Q2 revenue of $345.3 million, slightly above the IBES estimate of $345.2 million. More impressively, LifeStance's net income for the quarter came in at a loss of $3.8 million, significantly better than the expected loss of $9.87 million. The adjusted EBITDA for Q2 stood at $34 million, outperforming the IBES estimate of $31.1 million.

Adding to the positive sentiment, LifeStance provided an encouraging outlook for the third quarter of 2025. The company projects Q3 revenue between $345-365 million and adjusted EBITDA in the range of $33-39 million. This forward-looking guidance suggests continued growth and improved profitability, likely contributing to investors' enthusiasm and the subsequent pre-market stock surge.